Fortrea Holdings Inc. (NASDAQ:FTRE – Get Free Report) has been assigned an average recommendation of “Hold” from the twelve ratings firms that are currently covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating and four have given a buy rating to the company. The average 1-year price objective among analysts that have covered the stock in the last year is $16.75.
FTRE has been the subject of several research analyst reports. Evercore set a $25.00 target price on Fortrea and gave the stock an “outperform” rating in a research note on Tuesday, January 6th. Robert W. Baird set a $19.00 target price on shares of Fortrea in a research report on Wednesday, January 14th. TD Cowen upped their price target on shares of Fortrea from $7.00 to $15.00 and gave the stock a “hold” rating in a research report on Thursday, January 22nd. Citigroup upgraded Fortrea from a “neutral” rating to a “buy” rating and boosted their price objective for the stock from $12.00 to $21.00 in a research note on Thursday, December 11th. Finally, Wall Street Zen lowered Fortrea from a “buy” rating to a “hold” rating in a research note on Monday, October 27th.
Read Our Latest Stock Analysis on Fortrea
Hedge Funds Weigh In On Fortrea
Fortrea Trading Down 0.9%
Shares of Fortrea stock opened at $9.70 on Wednesday. The firm’s 50 day simple moving average is $16.01 and its two-hundred day simple moving average is $12.16. The firm has a market capitalization of $896.28 million, a price-to-earnings ratio of -0.86, a PEG ratio of 0.29 and a beta of 1.59. Fortrea has a 12-month low of $3.97 and a 12-month high of $18.67. The company has a current ratio of 1.00, a quick ratio of 1.00 and a debt-to-equity ratio of 1.81.
About Fortrea
Fortrea, Inc is a global contract development and manufacturing organization (CDMO) that provides integrated solutions for pharmaceutical and biotechnology companies. Established as a spin-off from Thermo Fisher Scientific’s Pharma Services business in October 2023, Fortrea leverages a legacy of scientific expertise and manufacturing scale to support drug development from early-stage research through commercial production. The company’s comprehensive offerings address the complex needs of both small-molecule and biologics programs, making it a single source for clients seeking to accelerate timelines and manage costs.
Fortrea’s core services encompass analytical and formulation development, process optimization, clinical and commercial manufacturing, and packaging services.
Featured Stories
- Five stocks we like better than Fortrea
- Energy Security Is Now National Security – Positioning Is Happening Now
- The gold chart Wall Street is terrified of…
- Have $500? Invest in Elon’s AI Masterplan
- Your Bank Account Is No Longer Safe
- This $15 Stock Could Go Down as the #1 Stock of 2026
Receive News & Ratings for Fortrea Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fortrea and related companies with MarketBeat.com's FREE daily email newsletter.
